Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: A systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 34, Issue 26, 2016, Pages 3157-3165

  Guenancia, Charles ^a,b   Lefebvre, Annick ^a,e   Cardinale, Daniela ^f   Yu, Anthony F ^g   Ladoire, Sylvain ^c,d   Ghiringhelli, François ^c,d   Zeller, Marianne ^b   Rochette, Luc ^b   Cottin, Yves ^a,b   Vergely, Catherine ^b  

^a University Hospital   (United States)

^b Institut Médical de Génétique et d Immunologie   (France)

^c Georges Francois Leclerc Cancer Center   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

^e REIMS UNIVERSITY HOSPITAL   (France)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TRASTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ARTICLE; BODY MASS; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; HUMAN; HYPERTENSION; INCIDENCE; META ANALYSIS; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; FEMALE; HEART DISEASES; ODDS RATIO;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BREAST NEOPLASMS; CARDIOTOXICITY; FEMALE; HEART DISEASES; HUMANS; OBESITY; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TRASTUZUMAB;

EID: 84989836055     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4846     Document Type: Article

References (65)

1. Pommier Y, Leo E, Zhang H, et al: DNA top-oisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17:421-433, 2010
2. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905, 1998
3. Keefe DL: Anthracycline-induced cardiomyopathy. Semin Oncol 28:2-7, 2001 (suppl 12)
4. Caram ME, Guo C, Leja M, et al: Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Res Treat 152:163-172, 2015
5. Rochette L, Guenancia C, Gudjoncik A, et al: Anthracyclines/trastuzumab: New aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 36:326-348, 2015
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
8. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
9. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
10. Klein PM, Dybdal N: Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 30:49-53, 2003 (suppl 16)
11. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
12. Farolfi A, Melegari E, Aquilina M, et al: Trastuzumab-induced cardiotoxicity in early breast cancer patients: A retrospective study of possible risk and protective factors. Heart 99:634-639, 2013
13. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329, 2004
14. De Pergola G, Silvestris F: Obesity as a major risk factor for cancer. J Obes 2013:291546, 2013
15. Zeller M, Steg PG, Ravisy J, et al: Relation between body mass index, waist circumference, and death after acute myocardial infarction. Circulation 118:482-490, 2008
16. de Azambuja E, McCaskill-Stevens W, Francis P, et al: The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145-153, 2010
17. Ladoire S, Dalban C, Roché H, et al: Effect of obesity on disease-free and overall survival in node-positive breast cancer patients in a large French population: A pooled analysis of two randomised trials. Eur J Cancer 50:506-516, 2014
18. Herman DR, Ganz PA, Petersen L, et al: Obesity and cardiovascular risk factors in younger breast cancer survivors: The Cancer and Menopause Study (CAMS). Breast Cancer Res Treat 93:13-23, 2005
19. Cardinale D, Colombo A, Bacchiani G, et al: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981-1988, 2015
20. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916, 2010
21. Yu AF, Yadav NU, Lung BY, et al: Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149:489-495, 2015
22. Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605, 2010
23. Plana JC, Galderisi M, Barac A, et al: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063-1093, 2014
24. Rücker G, Schwarzer G, Carpenter J: Arcsine test for publication bias in meta-analyses with binary outcomes. Stat Med 27:746-763, 2008
25. Harris RJ, Bradburn MJ, Deeks JJ, et al: metan: fixed- and random-effects meta-analysis. Stata J 8:3-28, 2008
26. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986
27. Simpson EH: The Interpretation of interaction in contingency tables. J R Stat Soc Series B Stat Methodol 13:238-241, 1951
28. Berlin JA, Laird NM, Sacks HS, et al: A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8:141-151, 1989
29. StataCorp: Stata/SE 10.0. College Station, TX, StataCorp, 2007
30. R Foundation for Statistical Computing: R: A language and environment for statistical computing. http://www.R-project.org
31. Rücker G: Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3: 312-324, 2012
32. Neupane B, Richer D, Bonner AJ, et al: Network meta-analysis using R: A review of currently available automated packages. PLoS One 9:e115065, 2014
33. Krahn U, Binder H, König J: A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35, 2013
34. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558, 2002
35. Ioannidis JP, Patsopoulos NA, Evangelou E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335:914-916, 2007
36. Sellen D: Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series No. 854. Pp. 452. (WHO, Geneva, 1995.)
37. Swiss Fr 71.00. J Biosoc Sci 30:135-144, 1998
38. Rothstein HR, Sutton AJ, Borenstein M (eds): Publication Bias in Meta-Analysis. Hoboken, NJ, John Wiley & Sons, 2006, pp 1-7 doi:10.1002/0470870168.ch1
39. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6: e1000097, 2009
40. Aitelhaj M, Lkhouyaali S, Rais G, et al: Cardiac safety of the adjuvant trastuzumab in a Moroccan population: Observational monocentric study of about 100 patients. BMC Res Notes 6:339, 2013
41. Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, et al: Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital. Int J Clin Pharm 37:365-372, 2015
42. Bonneterre J, Roché H, Kerbrat P, et al: Longterm cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. J Clin Oncol 22: 3070-3079, 2004
43. Fumoleau P, Roché H, Kerbrat P, et al: Longterm cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results. Ann Oncol 17:85-92, 2006
44. da Fonseca LG, de Melo Gagliato D, Takahashi TK, et al: Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experience. Breast Care (Basel) 9:255-260, 2014
45. Lemieux J, Diorio C, Côté MA, et al: Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 33:2569-2576, 2013
46. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
47. Serrano JM, Muñiz J, Del Castillo S, et al: Body mass index predicts cardiac toxicity following anthracycline-based chemotherapy. Circulation 128, 2013 (A16133)
48. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007
49. Ürun Y, Utkan G, Yalcin B, et al: The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer. Exp Oncol 37:53-57, 2015
50. Khouri MG, Douglas PS, Mackey JR, et al: Cancer therapy-induced cardiac toxicity in early breast cancer: Addressing the unresolved issues. Circulation 126:2749-2763, 2012
51. Lotrionte M, Biondi-Zoccai G, Abbate A, et al: Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 112:1980-1984, 2013
52. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
53. Telli ML, Hunt SA, Carlson RW, et al: Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol 25:3525-3533, 2007
54. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
55. Thavendiranathan P, Abdel-Qadir H, Fischer HD, et al: Breast cancer therapy-related cardiac dysfunction in adult women treated in routine clinical practice: A population-based cohort study. J Clin Oncol 34:2239-2246, 2016
56. Kenchaiah S, Evans JC, Levy D, et al: Obesity and the risk of heart failure. N Engl J Med 347:305-313, 2002
57. Mandviwala T, Khalid U, Deswal A: Obesity and cardiovascular disease: A risk factor or a risk marker? Curr Atheroscler Rep 18:21, 2016
58. Renehan AG, Tyson M, Egger M, et al: Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578, 2008
59. Rodvold KA, Rushing DA, Tewksbury DA: Doxorubicin clearance in the obese. J Clin Oncol 6:1321-1327, 1988
60. Mitra MS, Donthamsetty S, White B, et al: High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol 231:413-422, 2008
61. Guenancia C, Hachet O, Aboutabl M, et al: Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol 77:777-785, 2016
62. Nakamura K, Fuster JJ, Walsh K: Adipokines: A link between obesity and cardiovascular disease. J Cardiol 63:250-259, 2014
63. Maruyama S, Shibata R, Ohashi K, et al: Adiponectin ameliorates doxorubicin-induced cardiotoxicity through Akt protein-dependent mechanism. J Biol Chem 286:32790-32800, 2011
64. Ouchi N, Parker JL, Lugus JJ, et al: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85-97, 2011
65. Marinou K, Tousoulis D, Antonopoulos AS, et al: Obesity and cardiovascular disease: From pathophysiology to risk stratification. Int J Cardiol 138:3-8, 2010